In vitro inhibition of metabolism but not transport of gliclazide and repaglinide by Cree medicinal plant extracts.

[1]  P. Haddad,et al.  Populus balsamifera Extract and Its Active Component Salicortin Reduce Obesity and Attenuate Insulin Resistance in a Diet-Induced Obese Mouse Model , 2013, Evidence-based complementary and alternative medicine : eCAM.

[2]  P. Haddad,et al.  Larix laricina, an Antidiabetic Alternative Treatment from the Cree of Northern Quebec Pharmacopoeia, Decreases Glycemia and Improves Insulin Sensitivity In Vivo , 2012, Evidence-based complementary and alternative medicine : eCAM.

[3]  Nan Shang,et al.  Adipogenic constituents from the bark of Larix laricina du Roi (K. Koch; Pinaceae), an important medicinal plant used traditionally by the Cree of Eeyou Istchee (Quebec, Canada) for the treatment of type 2 diabetes symptoms. , 2012, Journal of ethnopharmacology.

[4]  P. Haddad,et al.  Populus balsamifera L. (Salicaceae) mitigates the development of obesity and improves insulin sensitivity in a diet-induced obese mouse model. , 2012, Journal of ethnopharmacology.

[5]  A. D. Rodrigues,et al.  Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. , 2010, British journal of clinical pharmacology.

[6]  S. Kumar,et al.  Drug–drug Interaction between Pravastatin and Gemfibrozil (Antihyperlipidemic) with Gliclazide (Antidiabetic) in Rats , 2010, Journal of young pharmacists : JYP.

[7]  W. Staines,et al.  Actions of ethnobotanically selected Cree anti-diabetic plants on human cytochrome P450 isoforms and flavin-containing monooxygenase 3. , 2009, Journal of ethnopharmacology.

[8]  M. Prentki,et al.  Evaluation of the antidiabetic potential of selected medicinal plant extracts from the Canadian boreal forest used to treat symptoms of diabetes: part II. , 2009, Canadian journal of physiology and pharmacology.

[9]  Haifeng Duan,et al.  Rhaponticin from rhubarb rhizomes alleviates liver steatosis and improves blood glucose and lipid profiles in KK/Ay diabetic mice. , 2009, Planta medica.

[10]  R. Day,et al.  Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide , 2008, British journal of pharmacology.

[11]  T. Johns,et al.  Medicinal plants of Cree communities (Québec, Canada): antioxidant activity of plants used to treat type 2 diabetes symptoms. , 2007, Canadian journal of physiology and pharmacology.

[12]  A. S. Gross,et al.  Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. , 2007, British journal of clinical pharmacology.

[13]  P. Artursson,et al.  Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers , 2007, Nature Protocols.

[14]  M. Prentki,et al.  Selected plant species from the Cree pharmacopoeia of northern Quebec possess anti-diabetic potential. , 2006, Canadian journal of physiology and pharmacology.

[15]  C. Leduc,et al.  Plants used by the Cree Nation of Eeyou Istchee (Quebec, Canada) for the treatment of diabetes: A novel approach in quantitative ethnobotany. , 2006, Journal of ethnopharmacology.

[16]  A. Mitra,et al.  MDR- and CYP3A4-mediated drug-herbal interactions. , 2006, Life sciences.

[17]  Sunmin Park,et al.  Insulin sensitizing and alpha-glucoamylase inhibitory action of sennosides, rheins and rhaponticin in Rhei Rhizoma. , 2006, Life sciences.

[18]  W. Haefeli,et al.  Opposite effects of short‐term and long‐term St John's wort intake on voriconazole pharmacokinetics , 2005, Clinical pharmacology and therapeutics.

[19]  G. Dresser,et al.  Natural products and adverse drug interactions , 2004, Canadian Medical Association Journal.

[20]  S. Krähenbühl,et al.  Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. , 2004, British journal of clinical pharmacology.

[21]  Ji-Young Park,et al.  Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide , 2003, Clinical pharmacology and therapeutics.

[22]  I. Bjørnsdottir,et al.  CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. , 2003, British journal of clinical pharmacology.

[23]  H. Lennernäs,et al.  CYP3A4, CYP3A5, and MDR1 in human small and large intestinal cell lines suitable for drug transport studies. , 2001, Journal of pharmaceutical sciences.

[24]  K. Gallicano,et al.  An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. , 2001, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[25]  M. Yoshikawa,et al.  Study on anti-Oketsu activity of rhubarb II. Anti-allergic effects of stilbene components from Rhei undulati Rhizoma (dried rhizome of Rheum undulatum cultivated in Korea). , 2001, Biological & pharmaceutical bulletin.

[26]  D. Back,et al.  Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. , 1999, British journal of clinical pharmacology.

[27]  S. Oliver,et al.  Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. , 1998, International journal of clinical pharmacology and therapeutics.

[28]  Y. Sugiyama,et al.  Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.

[29]  P. Watkins,et al.  Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. , 1997, Molecular pharmacology.

[30]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[31]  W. Staines,et al.  Cree antidiabetic plant extracts display mechanism-based inactivation of CYP3A4. , 2011, Canadian journal of physiology and pharmacology.

[32]  R. Lavielle,et al.  The mode of action and clinical pharmacology of gliclazide: a review. , 1991, Diabetes research and clinical practice.

[33]  K. Yoshida,et al.  The metabolism of gliclazide in man. , 1985, Xenobiotica; the fate of foreign compounds in biological systems.